Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Bullboard Posts
Comment by dt_coreon May 06, 2011 11:03am
277 Views
Post# 18540067

RE: RE: RE: Earnings Release

RE: RE: RE: Earnings ReleaseOn the last call, HEM guided to up 40% in the quarter YoY and they said it included the revenue that was pushed into the quarter, so don't expect anything different than the $21mm number. I'm much more interested in how the rest of the year is shaping up. $21mm was a given, now lets see how the remaining $50mm+ anticipated for the year looks. More importantly, need to see how margins/operating model are shaping up. The company guided to a slightly down year in terms of operating costs. Also, they think 50% margin achievable (although probably not in Q1 I suspect, but I want to see evidence of this improving towards or at 50% by end of year).

Management is still on a short leash in my books, but I'm willing to give them benefit of the doubt at this point and thus far Q1 top-line is coming in as expected. However, if at any point things appear to be slipping I will be writing to M. Lang and the board to seek shareholder value creation alternatives. HEM is not an overly large % of my PA, but I own enough shares to be taken seriously. I suggest others consider doing the same if need be.
Bullboard Posts